Biotech

Q1 2018 Share Price Performance

Analysis: Healthcare Outperforms the Market Starting this quarter, the Bloom Burton equity research team has taken over responsibility for the “Share Price Performance for the Canadian Healthcare Sector” blog from Wayne Schnarr. With the blog, Wayne created an essential light-reading but infor ...

Zymeworks has a 64 per cent upside, Paradigm Capital says

With a lead drug candidate in a Phase 1 clinical trial and a newly expanded partnership with Japanese pharma company Daiichi Sankyo, Zymeworks (TSX, NYSE:ZYME) deserves a big target price raise, says analyst Rahul Sarugaser from Paradigm Capital, who on Thursday reiterated his “Buy” rating with ...

Zymeworks is undervalued, Paradigm Capital says

Vancouver-based biopharm company Zymeworks Inc. (TSX:ZYME, NYSE:ZYME) is poised to be this decade’s next-generation drug development engine, says analyst Rahul Sarugaser of Paradigm Capital, who in a research note on Friday reiterated his “Buy” rating and $17.00 target price (all figures in U ...

Canada in Science – April 6, 2018

Welcome to your Canada in Science Review for April 6th, 2018! EMBO Rep.  2018 Mar 28. doi: 10.15252/embr.201744722. Stress Granules Counteract Senescence by Sequestration of PAI-1. Proc Natl Acad Sci USA.  2018 Mar 26. doi: 10.1073/pnas.1717015115. IpdAB, A Virulence Factor in Mycobacterium ...

I Cannot Own Commodities And Here's Why

Market Recap for Thursday, April 5, 2018 The latest recovery attempt continued into Thursday of this week, but weak futures this morning will provide yet one more obstacle for the bulls to overcome.  I'll talk more about that in the Pre-Market Action section below. In the meantime, eight of nin ...

These 3 Canadian ETFs hold top stocks, but only 2 are buys

These ETFs mostly hold high-quality stocks that are widely traded on Canadian exchanges. Each fund mirrors, or tracks, the performance of a major stock market index. That’s different from ETFs focused on narrower indexes or themes such as solar power and biotechnology. Of course, you pay brokerag ...

Acerus Pharma is ready to hit new highs, Mackie Research says

With product launches expected this year in Europe, Asia and the Middle East, specialty pharmacy company Acerus (TSX:ASP) is ready to hit new highs, says André Uddin of Mackie Research Capital, who on Wednesday reiterated his “Speculative Buy” rating and C$0.50 target price for Acerus. Acerus ...

Biotech in Countries Starting with “I” – Part 12: Israel

This is a guest post from Susan K Finston, President of Finston Consulting.  A little over five years ago I penned the first installment in this irregular series, focused on Israel’s tech transfer prowess and efforts to encourage innovative life-sciences. I tracked the Start-Up Nation’s incr ...

How is biotech combating these five killer diseases on the planet?

Biotechnology is a massive scientific field that uses research tools from biology and chemistry to solve problems and that includes human diseases too. Ever since its existence, it has revolutionized… The post How is biotech combating these five killer diseases on the planet? appeared first on Dr ...

Canada in Science – March 2, 2018

Welcome to your Canada in Science Review for March 2nd, 2018! Cell Stem Cell.  2018 Feb 1;22(2):177-190.e7. Inhibition of Methyltransferase setd7 Allows the In Vitro Expansion of myogenic Stem Cells with Improved Therapeutic Potential.   Proc Natl Acad Sci U S A.  2018 Feb 20. doi: 10.1073 ...